Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Clinical Drug Investigation
Erschienen in:

06.09.2024 | Systematic Review

The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

verfasst von: Peiwen Xue, Haiyan Qin, Di Qin, Yunzhou Shi, Huijing Li, Tian Luo, Caiyun Shi, Yeliu Wang, Zihao Zhao, Wei Cao, Zihao Zou, Qian Yang, Rongjiang Jin, Juan Li, Xianjun Xiao

Erschienen in: Clinical Drug Investigation | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The anti-pruritic effect of placebo in patients with chronic urticaria has gained increasing attention in clinical research. However, the extent of placebo effect and its influencing factors in the treatment of chronic urticaria are not well understood.

Objective

The objective of this systematic review and meta-analysis was to investigate the effect of placebo on pruritus in patients with chronic urticaria and to explore relevant influencing factors.

Methods

PubMed, Embase, Web of Science, Cochrane Library, and PsycINFO were searched from inception to 10 July, 2024. Primary outcome included pruritus scores. The secondary outcomes focused on global symptoms and quality of life. Subgroup analyses and meta-regression analyses were conducted based on drug types, sample size, participants’ age, and other variables. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and a trial sequential analysis were employed to establish the reliability of evidence.

Results

A total of 65 eligible publications (including 67 randomized controlled trials) involving 10,704 patients with chronic urticaria were included. The pruritus scores decreased following placebo treatment (moderate evidence). In addition, favorable results were observed in global symptoms (moderate evidence) and quality of life (low evidence) after placebo treatment. Subgroup analyses indicated that the type of active medication in intervention groups was an influencing factor of placebo effect of pruritus. Meta-regression analyses demonstrated that the anti-pruritic effect of placebo was inversely correlated with sample size and positively correlated with participants’ age. A trial sequential analysis provided further support for the anti-pruritic effect of placebo.

Conclusions

A substantial improvement of pruritus after placebo treatment was observed in patients with chronic urticaria. The anti-pruritic effect of placebo varied with sample size, participants’ age, and type of active medication used. Future research should further investigate the effect size of placebo and clarify the potential mechanism.

PROSPERO Registration

The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) as CRD42023482608.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401.CrossRefPubMed
2.
Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–32.CrossRefPubMed
3.
Li J, Mao D, Liu S, Liu P, Tian J, Xue C, et al. Epidemiology of urticaria in China: a population-based study. Chin Med J (Engl). 2022;135(11):1369–75.CrossRefPubMed
4.
Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–66.CrossRefPubMed
5.
Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16.CrossRefPubMed
6.
Giesey RL, Mehrmal S, Uppal P, Delost ME, Delost GR. Dermatoses of the world: burden of skin disease and associated socioeconomic status in the world. J Am Acad Dermatol. 2021;84(2):556–9.CrossRefPubMed
7.
Godse K, De A, Zawar V, Shah B, Girdhar M, Rajagopalan M, et al. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update. Indian J Dermatol. 2018;63(1):2–15.CrossRefPubMedPubMedCentral
8.
Jang YH, Kim SM, Eun DH, Park KD, Park GH, Kim BS, et al. Validity and reliability of itch assessment scales for chronic pruritus in adults: a prospective multicenter study. J Am Acad Dermatol. 2020;82(1):80–6.CrossRefPubMed
9.
Fjellner B, Arnetz BB. Psychological predictors of pruritus during mental stress. Acta Derm Venereol. 1985;65(6):504–8.CrossRefPubMed
10.
Bérard F, Saini S, Giménez-Arnau A, Hide M, Lebwohl M, Sussman G, et al. Fast symptom improvement and favorable safety profile with remibrutinib in chronic spontaneous urticaria: REMIX-1/-2 studies. Rev Fr Allergol. 2024;64(Supplement):103855.
11.
van Laarhoven AIM, van der Sman-Mauriks IM, Donders ART, Pronk MC, van de Kerkhof PCM, Evers AWM. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol. 2015;135(5):1234–43.CrossRefPubMed
12.
Meeuwis SH, van Middendorp H, van Laarhoven AIM, van Leijenhorst C, Pacheco-Lopez G, Lavrijsen APM, et al. Placebo and nocebo effects for itch and itch-related immune outcomes: a systematic review of animal and human studies. Neurosci Biobehav Rev. 2020;113:325–37.CrossRefPubMed
13.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;21(358): j4008.CrossRef
14.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;2(350): g7647.CrossRef
15.
16.
Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009;34(18):1929–41.CrossRefPubMed
17.
Shi J, Luo D, Weng H, Zeng XT, Lin L, Chu H, Tong T. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641–54.CrossRefPubMed
18.
19.
Burda BU, O’Connor EA, Webber EM, Redmond N, Perdue LA. Estimating data from figures with a Web-based program: considerations for a systematic review. Res Synth Methods. 2017;8(3):258–62.CrossRefPubMed
20.
Petzold A, Steeb T, Wessely A, Koch EAT, Vera J, Berking C, et al. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Cancer Treat Rev. 2023;115: 102543.CrossRefPubMed
21.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28(366): l4898.CrossRef
22.
23.
Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137.PubMedPubMedCentral
24.
25.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.CrossRefPubMedPubMedCentral
26.
Abu Shareeah AM, Youssuf M, Deckers I, De Mahieu C, Coulie PJ. Double-blind, parallel, randomized pilot study comparing the efficacy and tolerance of cetiririne 10 mg, mequitazine 2 × 5 mg and placebo in the treatment of patients suffering from chronic urticaria: comparison of suppressive effects on histamine-induced weals and flares. Drug Dev Res. 1998;43(4):185–92.CrossRef
27.
Bernstein IL, Bernstein DI. Efficacy and safety of astemizole, a long-acting and nonsedating Hsub 1 antagonist for the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;77(1I):37–42.CrossRefPubMed
28.
Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother. 1996;30(10):1075–9.CrossRefPubMed
29.
Brostoff J, Fitzharris P, Dunmore C, Theron M, Blondin P. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy. 1996;51(5):320–5.CrossRefPubMed
30.
Camarasa JMG, Aliaga A, Fernández-Vozmediano JM, Fonseca E, Iglesias L, Tagarro I. Azelastine tablets in the treatment of chronic idiopathic urticaria: phase III, randomised, double-blind, placebo and active controlled multicentric clinical trial. Skin Pharmacol Appl Skin Physiol. 2001;14(2):77–86.CrossRefPubMed
31.
Di Lorenzo G, Pacor ML, Mansueto P, Esposito Pellitteri M, Lo Bianco C, Ditta V, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol. 2004;114(3):619–25.CrossRefPubMed
32.
Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol. 1999;12(1):16–24.PubMed
33.
Dubertret L, Pecquet C, Murrieta-Aguttes M, Leynadier F. Mizolastine in primary acquired cold urticaria. J Am Acad Dermatol. 2003;48(4):578–83.CrossRefPubMed
34.
Dubertret L, Zalupca L, Cristodoulo T, Benea V, Medina I, Fantin S, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol. 2007;17(3):223–8.PubMed
35.
Elhendawy M, Hagras MM, Soliman SS, Shaker ESE. Positive effect of Helicobacter pylori treatment on outcome of patients with chronic spontaneous urticaria: a randomized double-blind pilot study. Am J Clin Pathol. 2021;155(3):405–11.CrossRefPubMed
36.
Ferguson J, MacDonald KJS, Kenicer KJA. Terfenadine and placebo compared in the treatment of chronic idiopathic urticaria: a randomised double-blind study. Br J Clin Pharmacol. 1985;20(6):639–41.CrossRefPubMedPubMedCentral
37.
Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071–8.CrossRefPubMed
38.
Fox RW, Lockey RF, Bukantz SC, Serbousek D. The treatment of mild to severe chronic idiopathic urticaria with astemizole: double-blind and open trials. J Allergy Clin Immunol. 1986;78(6):1159–66.CrossRefPubMed
39.
Gibson JR, Harvey SG, Barth JH, Moss MY, Burke CA. An assessment of the novel antihistamine BW 825C in the treatment of chronic idiopathic urticaria: a placebo-controlled study. Dermatologica. 1984;169(4):179–83.CrossRefPubMed
40.
Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007;62(5):539–46.CrossRefPubMed
41.
Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol. 2008;22(1):87–93.CrossRefPubMed
42.
Hide M, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: a double-blind, randomized, multicenter, placebo-controlled clinical trial. Allergol Int. 2019;68(1):59–67.CrossRefPubMed
43.
Hide M, Yagami A, Togawa M, Saito A, Furue M. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study. Allergol Int. 2017;66(2):317–25.CrossRefPubMed
44.
Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol. 1988;119(1):67–71.CrossRefPubMed
45.
Juhlin L, Gibson JR, Harvey SG, Huson LW. Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria: a double-blind, placebo-controlled study. Int J Dermatol. 1987;26(10):653–4.CrossRefPubMed
46.
Kailasam V, Mathews KP. Controlled clinical assessment of astemizole in the treatment of chronic idiopathic urticaria and angioedema. J Am Acad Dermatol. 1987;16(4):797–804.CrossRefPubMed
47.
Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86(6 Pt 2):1014–8.CrossRefPubMed
48.
Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662–9.CrossRefPubMed
49.
Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol. 2006;45(4):469–74.CrossRefPubMed
50.
Metz M, Scholz E, Med C, Ferrán M, Izquierdo I, Giménez-Arnau A, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol. 2010;104(1):86–92.CrossRefPubMed
51.
Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48(4):535–41.CrossRefPubMed
52.
Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–22.CrossRefPubMed
53.
Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34(9):1401–7.CrossRefPubMed
54.
Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol. 2007;8(1):37–42.CrossRefPubMed
55.
Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria: a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy. 2001;31(10):1607–14.CrossRefPubMed
56.
Paul E, Berth-Jones J, Ortonne JP, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat. 1998;9(3):143–9.CrossRef
57.
Peremans W, Mertens RLJ, Morias J, Campaert H. Oxatomide in the treatment of chronic urticaria: a double-blind placebo-controlled trial. Dermatologica. 1981;162(1):42–50.CrossRefPubMed
58.
Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40(1):72–6.CrossRefPubMed
59.
Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol. 1993;129(5):580–3.CrossRefPubMed
60.
Zuberbier T, Münzberger C, Haustein U, Trippas E, Burtin B, Mariz SD, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology. 1996;193(4):324–7.CrossRefPubMed
61.
Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–28.CrossRefPubMed
62.
Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy. 2013;68(7):921–8.CrossRefPubMed
63.
Weller K, Gimenez-Arnau AM, Baron J, Brehler R, Ferrer M, Groffik A, et al. Efficacy and safety of on-demand versus daily rupatadine in chronic spontaneous urticaria: a randomized trial. Allergy. 2024;79(1):93–103.CrossRefPubMed
64.
Maurer M, Berger W, Giménez-Arnau A, Hayama K, Jain V, Reich A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;150(6):1498-506.e2.CrossRefPubMed
65.
Hide M, Maeda Y, Oshima N, Hisada S. A Phase III clinical trial of desloratadine in Japanese subjects with chronic urticaria: a randomized controlled trial. J Clin Ther Med. 2016;32(11):891–903.
66.
Gimenez-Arnau AM, Maurer M, Bernstein J, Sitz K, Hide M, Sussman G, et al. Evaluating complete control of urticaria with ligelizumab: a composite score of symptoms and quality-of-life outcome. Allergy. 2021;76(Suppl. 110):617–8.
67.
Gimenez-Arnau AM, Spector S, Antonova E, Trzaskoma B, Rosen K, Omachi TA, et al. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies. Clin Transl Allergy. 2016;6:32.CrossRefPubMedPubMedCentral
68.
Hide M, Igarashi A, Yagami A, Chinuki Y, Inomata N, Fukunaga A, et al. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: subgroup analysis of the phase 3 POLARIS study. Allergol Int. 2018;67(2):243–52.CrossRefPubMed
69.
Hide M, Park HS, Igarashi A, Ye YM, Kim TB, Yagami A, et al. Efficacy and safety of omalizumab in Japanese and Korean patients with chronic spontaneous/idiopathic urticaria (CSU/-CIU): results from the phase III POLARIS study. J Am Acad Dermatol. 2017;76(6):AB112.CrossRef
70.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–9.CrossRefPubMed
71.
Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202-9.e5.CrossRefPubMed
72.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321–32.CrossRefPubMed
73.
Maurer M, Rosen K, Hsieh H-J, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New Engl J Med. 2013;368(10):924–35.CrossRefPubMed
74.
Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H-1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-U195.CrossRefPubMed
75.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75.CrossRefPubMed
76.
Yuan W, Hu S, Li M, Yang L, Liu L, Zheng M, et al. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Dermatol Ther. 2022;35(4): e15303.CrossRefPubMedPubMedCentral
77.
Metz M, Torene R, Kaiser S, Beste MT, Staubach P, Bauer A, et al. Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. Allergy. 2019;74(1):141–51.CrossRefPubMed
78.
Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy. 2016;71(8):1135–44.CrossRefPubMed
79.
Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;138(6):1730–2.CrossRefPubMed
80.
Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659–61.CrossRefPubMed
81.
Kaplan A, Ferrer M, Bernstein JA, Antonova E, Trzaskoma B, Raimundo K, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2016;137(2):474–81.CrossRefPubMed
82.
Bonnekoh H, Butze M, Spittler S, Staubach P, Weller K, Scheffel J, et al. Inhibition of interleukin-1 with rilonacept is not effective in cold urticaria-Results of a randomized, placebo-controlled study. Clin Transl Allergy. 2023;13(3): e12226.CrossRefPubMedPubMedCentral
83.
Grattan CEH, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic “idiopathic” urticaria. Br J Dermatol. 2000;143(2):365–72.CrossRefPubMed
84.
Magerl M, Rother M, Bieber T, Biedermann T, Brasch J, Dominicus R, et al. Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2013;27(3):e363–9.CrossRefPubMed
85.
Morgan M, Cooke A, Rogers L, Adams-Huet B, Khan DA. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2014;2(5):601–6.
86.
Oliver ET, Chichester K, Devine K, Sterba PM, Wegner C, Vonakis BM, et al. Effects of an oral CRTh2 antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria. Int Arch Allergy Immunol. 2019;179(1):21–30.CrossRefPubMed
87.
Metz M, Sussman G, Gagnon R, Staubach P, Tanus T, Yang WH, et al. Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27(11):1961–9.CrossRefPubMedPubMedCentral
88.
Bi XD, Lu BZ, Pan XX, Liu S, Wang JY. Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial. Allergy Asthma Clin Immunol. 2021;17(1):39.CrossRefPubMedPubMedCentral
89.
Goldsobel AB, Rohr AS, Siegel SC, Spector SL, Katz RM, Rachelefsky GS, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;78(5 Pt 1):867–73.CrossRefPubMed
90.
Grant JA, Bernstein DI, Buckley CE, Chu T, Fox RW, Rocklin RE, et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1988;81(3):574–9.CrossRefPubMed
91.
Blythe JS, Thomaidou MA, Peerdeman KJ, van Laarhoven AIM, van Schothorst MME, Veldhuijzen DS, et al. Placebo effects on cutaneous pain and itch: a systematic review and meta-analysis of experimental results and methodology. Pain. 2023;164(6):1181–99.CrossRefPubMed
92.
Burke MJ, Romanella SM, Mencarelli L, Greben R, Fox MD, Kaptchuk TJ, et al. Placebo effects and neuromodulation for depression: a meta-analysis and evaluation of shared mechanisms. Mol Psychiatry. 2022;27(3):1658–66.CrossRefPubMed
93.
Migliorini F, Maffulli N, Eschweiler J, Betsch M, Tingart M, Colarossi G. Placebo effect in pharmacological management of fibromyalgia: a meta-analysis. Br Med Bull. 2021;139(1):73–85.CrossRefPubMed
94.
Quattrone A, Barbagallo G, Cerasa A, Stoessl AJ. Neurobiology of placebo effect in Parkinson’s disease: what we have learned and where we are going. Mov Disord. 2018;33(8):1213–27.CrossRefPubMed
95.
Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23.CrossRefPubMed
96.
Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother Psychosom. 2018;87(4):204–10.CrossRefPubMed
97.
Annoni M, Miller FG. Placebo effects and the ethics of therapeutic communication: a pragmatic perspective. Kennedy Inst Ethics J. 2016;26(1):79–103.CrossRefPubMed
98.
Geers AL, Kosbab K, Helfer SG, Weiland PE, Wellman JA. Further evidence for individual differences in placebo responding: an interactionist perspective. J Psychosom Res. 2007;62(5):563–70.CrossRefPubMed
99.
Vase L, Vollert J, Finnerup NB, Miao X, Atkinson G, Marshall S, et al. Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials. Pain. 2015;156(9):1795–802.CrossRefPubMed
100.
Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response: an evaluation of systematic reviews and meta-analyses across medicine. Gerontology. 2015;61(2):97–108.CrossRefPubMed
101.
Enck P, Klosterhalfen S. Does sex/gender play a role in placebo and nocebo effects? Conflicting evidence from clinical trials and experimental studies. Front Neurosci. 2019;13:160.CrossRefPubMedPubMedCentral
102.
Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.CrossRefPubMedPubMedCentral
103.
Lin C, Cai X, Yang W, Lv F, Nie L, Ji L. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Med. 2020;18(1):322.CrossRefPubMedPubMedCentral
104.
Pereira MP, Zeidler C, Szymczak H, Bischoff C, Tsianakas A, Ständer S, et al. Acceptability and perceived benefits of validated pruritus assessment instruments in the dermatological office and clinic: the perspectives of patients and physicians. J Eur Acad Dermatol Venereol. 2024. https://​doi.​org/​10.​1111/​jdv.​20148.CrossRefPubMed
Metadaten
Titel
The Effect of Placebo on Pruritus in Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
verfasst von
Peiwen Xue
Haiyan Qin
Di Qin
Yunzhou Shi
Huijing Li
Tian Luo
Caiyun Shi
Yeliu Wang
Zihao Zhao
Wei Cao
Zihao Zou
Qian Yang
Rongjiang Jin
Juan Li
Xianjun Xiao
Publikationsdatum
06.09.2024
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 9/2024
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-024-01389-5

Weitere Artikel der Ausgabe 9/2024

Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis

  • Systematic Review

Correction to: AVT04: An Ustekinumab Biosimilar

  • Open Access
  • Correction

Disability and Adverse Effects of Oral Versus Long-Acting Injectable Antipsychotics in Schizophrenia-Spectrum and Bipolar Disorder: A Comparison Based on Data-Driven Taxonomy

  • Open Access
  • Original Research Article

Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy

  • Open Access
  • Original Research Article

Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Open Access
  • Systematic Review

The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease

  • Open Access
  • Original Research Article